Coherus Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHRS research report →
Range $1.05 – $11
Price Chart
About the company
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies.
- CEO
- Dennis Lanfear
- IPO
- 2014
- Employees
- 145
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on CHRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $57.15M
- P/E
- -0.38
- Fwd P/E
- 12.95
- PEG
- -0.01
- P/S
- 1.07
- P/B
- 2.27
- EV/EBITDA
- -0.51
- Div Yield
- 0.00%
- Gross Margin
- 66.50%
- Op Margin
- -275.94%
- Net Margin
- -252.02%
- ROE
- -239.55%
- ROIC
- -180.06%
Latest fiscal year · YoY change
- Revenue
- $42.17M-84.2%
- Gross Profit
- $24.43M-83.6%
- Op Income
- $-179,534,000
- Net Income
- $-170,291,000-697.4%
- EPS
- $-1.45-680.0%
- OCF Growth
- -577.7%
- FCF Growth
- -577.7%
- 52W High
- $2.62
- 52W Low
- $0.36
- 50D MA
- $0.97
- 200D MA
- $1.43
- Beta
- 1.03
- RSI (14)
- 23
- Avg Volume
- 1.80M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Coherus narrowed its oncology focus to esophageal cancer for tagmokitug, cut costs sharply, and said LOQTORZI sales growth remains on track despite quarterly lumpiness.· November 9, 2026
- Tagmokitug development is being refocused on esophageal cancer, with management citing the strongest signal in both second-line and first-line studies.
- Coherus announced a projected 30% headcount reduction and said cost savings should lower quarterly LOQTORZI sales needed to cover core burn from $30 million-$35 million to $25 million-$30 million.
- Q3 LOQTORZI net sales were $14 million, up 3% sequentially and 25% year over year, but below the company’s 10% to 15% quarterly growth target.
- Management plans to meet with the FDA in early 2027 on dose selection and the next esophageal study design, with accelerated approval remaining a stated goal.
- The company said its cash runway is less than 12 months without additional benefits from cost cuts, potential milestone payments, or ex-U.S. deals.
Q3 2026 LOQTORZI net sales were $14 million, up 3% quarter over quarter and 25% year over year. Cash, cash equivalents and investments were $83.6 million at the end of Q3 2026, down from $105.3 million at the end of Q2; cash used in operations was $34 million, down 43% from the quarterly average in the first half of 2026. R&D expense from continuing operations was $22.6 million versus $27.3 million a year ago, and SG&A was $21.2 million versus $24.9 million a year ago. Management lowered full-year 2026 LOQTORZI revenue outlook to $54 million to $57 million and reaffirmed full-year 2026 combined OpEx of $170 million to $175 million. It also said quarterly LOQTORZI revenue required to cover core burn now falls to $25 million to $30 million from $30 million to $35 million previously. The company said without cost reductions, milestone payment benefits, or ex-U.S. deals, cash runway is less than 12 months from the filed 10-Q date.
Denny Lanfear framed the quarter as a strategic reset, saying Coherus has transformed from a biosimilars company into an oncology company and is now concentrating resources on the highest-probability path for tagmokitug. His tone was confident and decisive: he repeatedly emphasized esophageal cancer as the best-in-disease opportunity and said the company is prepared to pursue partnering, regulatory discussions, and a leaner operating structure. He also stressed that LOQTORZI growth needs to accelerate over the next several quarters to support the business.
Bryan McMichael highlighted tighter liquidity and the rationale for the restructuring. He said the company ended Q3 with $83.6 million in cash, cash equivalents and investments, used $34 million in operations, and refinanced a $38.7 million term loan with a new $55 million term loan, which added $11.5 million net to the balance sheet. He said the planned 30% headcount reduction, from about 140 to 100 FTEs, should create recurring savings of $6 million to $7 million per quarter, with most of that realized within two quarters, and that the company is preserving substantially all of the commercial team.
Analysts pressed on whether the second-line esophageal program could use ORR or PFS to support accelerated approval, and management said FDA precedent exists for esophageal cancer studies spanning both histologies and for ORR with durability in discussions. They said the next step is an FDA meeting in the first quarter of 2027 after submitting the package at the end of this year or early next year. Questions on the first-line opportunity drew the response that more durability, CBR, and PFS data are needed before a meaningful FDA conversation, and management said the first-line effort could run in parallel but second line is the priority. On commercial growth, management said the main levers are reducing chemo-only use, converting off-label IO patients, and expanding payer and clinical organization partnerships.
The strongest bull case from the call is that Coherus now has a clearer, narrower development path for tagmokitug with early signals in a difficult cancer and a plausible regulatory route. Management also believes LOQTORZI has room to grow meaningfully from a 20% to 22% share base, helped by physician awareness, payer step edits, and stronger utilization efforts. The cost reset should reduce burn and lower the revenue bar needed for self-sustainability.
The main risks are liquidity and execution: management explicitly said cash runway is less than 12 months without added savings, milestone proceeds, or ex-U.S. partnering. LOQTORZI growth also remains uneven, with Q3 sales below plan because of slower new patient starts in some territories. On the pipeline side, the esophageal strategy still needs FDA alignment, and the company is relying on additional data and future meetings before a final regulatory path is established.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.7%
- Shares Outstanding
- 154.54M
- Float Shares
- 147.93M
of shares held by institutions
153 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 11.74M | ▼ 261.31K |
| Vanguard Group Inc | 10.03M | ▼ 292.21K |
| Vanguard Capital Management LLC | 5.60M | ▼ 351.15K |
| Samsara Biocapital, LLC | 3.43M | 0 |
| Geode Capital Management, LLC | 3.10M | ▼ 586.83K |
| Kohlberg Kravis Roberts & Co. L.P. | 3.04M | 0 |
| State Street Corp | 2.43M | ▲ 44.47K |
| Two Sigma Investments, LP | 2.26M | ▼ 42.59K |
| Cm Management, LLC | 2.10M | 0 |
| C Worldwide Group Holding A/S | 1.93M | 0 |
| Alyeska Investment Group, L.P. | 1.73M | ▼ 516.77K |
| Hudson Bay Capital Management LP | 1.73M | ▲ 40.00K |
Held by 132 ETFs
Biggest fund positions in CHRS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | Satvat Ali J. | other | 60,000 |
| Jun 5, 26 | Satvat Ali J. | other | 30,000 |
| Jun 5, 26 | Karachun Rita A | other | 60,000 |
| Jun 5, 26 | Karachun Rita A | other | 30,000 |
| Jun 5, 26 | Newcomer Lee Nisley | other | 60,000 |
| Jun 5, 26 | Newcomer Lee Nisley | other | 30,000 |
| Jun 5, 26 | Ryan Michael Lee | other | 60,000 |
| Jun 5, 26 | Ryan Michael Lee | other | 30,000 |
| Jun 5, 26 | O'Donnell-Tormey Jill | other | 60,000 |
| Jun 5, 26 | O'Donnell-Tormey Jill | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CHRS coverage
Recent articles, reports, and earnings notes.
No research on CHRS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHRS report →Here's Why Coherus Oncology (CHRS) Is a Great 'Buy the Bottom' Stock Now
zacks.com · Nov 18
Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround
zacks.com · Nov 13
Coherus Oncology: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 10
Coherus Oncology, Inc. (CHRS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What Coherus Oncology (CHRS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 9
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
globenewswire.com · Nov 9
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know
zacks.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.